To inform debates around how the IRA may affect development of treatments for rare diseases, we examined how many orphan drugs approved by the US Food and Drug Administration (FDA) have had supplemental (follow-on) approved indications.
To inform debates around how the IRA may affect development of treatments for rare diseases, we examined how many orphan drugs approved by the US Food and Drug Administration (FDA) have had supplemental (follow-on) approved indications.